Asthma, COPD and Cystic Fibrosis, Expected to Witness the Rise of Personalized Therapies and Smart Devices, predicts Roots Analysis

Roots Analysis announced the addition of “Novel Drugs and Smart Devices for Respiratory Disorders, 2018-2030” report to its list of offerings.

Rohit Kumar, the principal analyst, stated, “The continuous investment in this domain has led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients.”

The report presents opinions on several key aspects of the market. Among other elements, it includes:

• A discussion on the novel therapies under development for treatment of asthma, COPD and cystic fibrosis. The report provides information on developers, phase of development of candidate drugs / therapies, mechanism of action, route of administration, type of molecule, type of formulation and the dosing frequency of various therapies.
• An analysis of the key unmet needs across asthma, COPD and cystic fibrosis. The study presents insights generated from real-time data on unmet needs identified from social media posts, recent publications, patient blogs and discussions of key opinion leaders.
• An extensive review of the development portfolio and key initiatives undertaken by established players (players with approved / late-stage drug candidates)
• An assessment of key players involved in the development of smart inhalers. It provides information on the development status of various products, type of inhalers and key collaborators. In addition, the report provides a comparative assessment of the various smart inhalers on the basis of several parameters, such as availability of Bluetooth, USB connection, reminder function and rechargeable options.
• A discussion on the regulatory landscape relate to the approval of combination products (drugs and inhalers), as well as smart inhalers in different countries.

Kumar further added, “The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.”

The research covers detailed profiles and assesses product portfolios of the following companies:

• AstraZeneca
• Boehringer Ingelheim
• Chiesi Pharmaceuticals
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical
• Vertex Pharmaceuticals
• Sanofi

For additional details, please visit https://www.rootsanalysis.com/reports/view_document/novel-drugs-and-smart-devices-for-respiratory-disorders-2018-2030-/188 or email sales@rootsanalysis.com

Contact:

Gaurav Chaudhary

Tel: +1-604-595-4954
Email: gaurav.chaudhary@rootsanalysis.com